|
Two new anti-impotence
drugs were released in areas of Europe such as Britain and
Germany, as well as in Australia, to compete against Pfizer’s
Viagra.
U.S. firms Eli
Lilly and Icos Corp. released the drug Cialis, while Bayer
came out with Levitra, also known as vardenafil.
Viagra was introduced
five years ago to treat impotence and has had much commercial
success--in 2002 alone, global sales reached $1.74 billion.
All three drugs
work by blocking the PDE-5 enzyme, which affects blood flow
to the penis. However, the new drugs claim to provide a more
effective treatment, including being longer lasting, than
has been offered in the past. And, rivals see room for growth
in the market, as only 10 percent to 15 percent of the 30
million men with impotence in Europe receive treatment, according
to Eli Lilly.
Anti-impotence
drugs have created a major market on the Internet as well,
though concern has been voiced about patients not having to
consult a doctor to receive the medication. Certain Web sites
have begun to offer Cialis already--for a price of up to $113
for four pills, a cost that is more than three times the price
through the government-funded National Health Service.
According to an
Eli Lilly representative, Cialis should be prescribed only
by doctors and should not be taken by men who have had a recent
stroke or heart attack or who have unstable angina.
The U.S. Food and
Drug Administration has not yet cleared Cialis and Levitra,
but both drugs are expected to be available in the United
States in the second half of 2003.
Reuters
February 4, 2003
Reuters
February 5, 2003
|